Member news

Boyds, a leading global drug development consultancy, is pleased to announce the appointment of Laurence Skillern as Chief Medical Officer.

EnteroBiotix announced that the first patient has been dosed in RISE, its Phase 2b clinical trial evaluating EBX-102-02 in moderate-to-severe irritable bowel syndrome with constipation (IBS-C).

Coulter Partners successfully led a search for Salvia BioElectronics B.V. to place Jill Schiaparelli as Chair of its Board of Directors.

Myricx Bio reached agreement to be acquired by Novartis for up to $1.5 billion.

Astex has entered into an exclusive, worldwide research collaboration and license agreement with Genentech.

Brandon Capital announced the successful exit of its portfolio company Myricx Bio.

Craig Marshall, $1.5B OrganOx exit CEO, joins Oxford Medical Products board

Innovation Orbit 2026 is FI Group by EPSA’s international guide to grants, R&D tax credits and public incentives for businesses planning R&D, CAPEX, digital transformation or decarbonisation projects.

KQ Labs, a leading accelerator that has helped early-stage life sciences innovators raise over £230 million, is now accepting applications for its ninth programme

Global drug development consultancy, Boyds has achieved a Bronze Medal from EcoVadis, a global leader in business sustainability assessments.

MDC welcomes new Chair from January 2027 to drive impact as next-generation technologies and collaborations reshape drug discovery

Columbus has published a new whitepaper, Digital Compliance for MedTech: Managing Regulatory Complexity.

BioInnovation Institute (BII) has chosen Victoria House in London as the location for its UK base.

With $47 million in seed funding now secured, TRIMTECH Therapeutics is accelerating development of its TRIMTAC and TRIMGLUE portfolio — a novel approach to eliminating disease-causing proteins.

IMU Biosciences announce their new strategic partnership with Waters Biosciences to accelerate the development of IMU’s next-generation AI-powered High Definition (HD) Immunology Platform. The partnership will bring together Waters Biosciences’ advanced flow cytometry and single-cell technologies with IMU's HD analysis and proprietary AI and machine learning analytics to turn complex immune data into insights at scale across discovery, translational, and clinical research applications.

RQ Bio announces the completion of an oversubscribed $115 million (£85.5 million) Series A financing.

Coulter Partners successfully led a search for Cellcolabs and to place Metzler, Ph.D., as Chief Executive Officer (CEO).

Precision BioSearch supports AdvanCell to appoint Justyna Kelly as CTO.

New technology improves long term efficacy, cost and safety, eliminating trial-and-error in DNA design

More than 1,600 local students from 49 schools across east Kent have taken part in the region’s largest ever science jamboree.